Carrier-Free Nanocombo-Sensitized Photoimmunotherapy via Activation of α2-Adrenergic Receptors
ACS Applied Materials & Interfaces · 2025
DOI: 10.1021/acsami.4c18052 ↗At a glance
Journal article in ACS Applied Materials & Interfaces, 2025. Written by XiaoKai Chi and 5 co-authors. Institution: Shulan International Medical College, Zhejiang Shuren University, Hangzhou 310015, PR China. Major MEDLINE topics: Photosensitizing Agents, Immunotherapy, Nanoparticles, Porphyrins. Cited 2 times so far (Crossref); 34 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: National Natural Science Foundation of China.
Abstract (original language)
Photodynamic therapy (PDT)-based photoimmunotherapy has attracted increasing attention in the field of cancer immunotherapy. Nonetheless, monotherapy alone proves insufficient in eliciting robust and enduring tumor immunogenicity within the "cold" microenvironment of triple-negative breast cancer. Therefore, it is imperative to integrate phototherapy and immunostimulation strategies to achieve synergistic effects. Here, we developed a carrier-free nanocombo comprising a photosensitizer (chlorin e6, Ce6) and an α2-adrenergic receptor (α2-AR) agonist (guanfacine, GFC) to enhance photoimmunotherapy through α2-AR activation. Ce6 and GFC possessed the ability to self-assemble into spherical nanoparticles, with the resulting Ce6-GFC (CeG) exhibiting exceptional drug loading efficiency (approaching 100%) and long-lasting colloidal stability, along with effective in vivo tumor-targeting capabilities. Following near-infrared laser irradiation, CeG-mediated phototherapy instigated a rapid generation of reactive oxygen species, leading to membrane disruption and the release of tumor-associated antigens, thereby facilitating dendritic cell maturation. Furthermore, α2-AR agonists served to repolarize M2 tumor-associated macrophages toward the M1 phenotype via adenylyl cyclase-mediated activation of α2-AR, thereby promoting the recruitment and activation of cytotoxic T lymphocytes. As a result, the carrier-free nanocombo significantly enhanced the efficacy of photoimmunotherapy in combatting poorly immunogenic breast tumors in female mice. Our findings showcase a "killing two birds with one stone" approach that boosts tumor immunogenicity, mitigates tumor immunosuppression, and advances the field of photoimmunotherapy.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Shulan International Medical College, Zhejiang Shuren University, Hangzhou 310015, PR China.
- College of Pharmacy, Jiamusi University, Jiamusi 154007, PR China.
- Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, PR China.
ORCID profiles: Yong-Zhong Du, Xiao-Ling Xu
Funding
- National Natural Science Foundation of China
Cite
APA
Chi, X., Wang, S. H., Gao, J., Su, J., Du, Y. Z., & Xu, X. L. (2025). Carrier-Free Nanocombo-Sensitized Photoimmunotherapy via Activation of α2-Adrenergic Receptors. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.4c18052
Vancouver
Chi X, Wang SH, Gao J, Su J, Du YZ, Xu XL. Carrier-Free Nanocombo-Sensitized Photoimmunotherapy via Activation of α2-Adrenergic Receptors. ACS Applied Materials & Interfaces. 2025. doi:10.1021/acsami.4c18052
BibTeX
@article{Chi2025,
author = {Chi, XiaoKai and Wang, Si-Hui and Gao, JingJing and Su, Jin and Du, Yong-Zhong and Xu, Xiao-Ling},
title = {Carrier-Free Nanocombo-Sensitized Photoimmunotherapy via Activation of α2-Adrenergic Receptors},
journal = {ACS Applied Materials & Interfaces},
year = {2025},
doi = {10.1021/acsami.4c18052}
}
EUVIMED